US69012T3059 - Common Stock
OUTLOOK THERAPEUTICS INC
NASDAQ:OTLK (3/27/2024, 8:00:03 PM)
After market: 9.2819 -0.09 (-0.94%)9.37
+0.69 (+7.95%)
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. The company is headquartered in Iselin, New Jersey and currently employs 24 full-time employees. The company went IPO on 2016-06-13. The firm focuses on developing and commercializing ONS-5010 (LYTENAVA (bevacizumab-vikg)), an ophthalmic formulation of bevacizumab for use in retinal indications. The firm's product candidate, ONS-5010, which is developed to be administered as an intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab is a full-length, humanized anti- Vascular Endothelial Growth Factor (VEGF) recombinant monoclonal antibody (mAb), that inhibits VEGF and associated angiogenic activity. VEGF is a protein that promotes the growth of new abnormal blood vessels. Its biologics license application (BLA) for ONS-5010 in wet AMD involved three clinical trials, which include NORSE ONE, NORSE TWO and NORSE THREE. The firm sells ONS-5010 in the United States, United Kingdom, Europe, Japan and other markets.
OUTLOOK THERAPEUTICS INC
485 Route 1 South, Building F, Suite 320
Iselin NEW JERSEY 08852
P: 16096193990
CEO: Lawrence A. Kenyon
Employees: 24
Website: https://outlooktherapeutics.com/
Wondering how the US markets performed in the middle of the day on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.
Which stocks are gapping on Friday?
Curious about the stocks that are showing activity before the opening bell on Friday?
Positive opinion serves as a basis for final decision for potential authorization from the European Commission (EC), expected within 67 days ISELIN, N.J.,...
ISELIN, N.J., March 18, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevacizumab for the treatment of retinal diseases in the US and the EU, today announced that it has closed its previously announced private placement, for upfront gross proceeds of approximately $60 million from the issuance and sale of shares of the Company’s common stock and accompanying warrants, before deducting placement agent fees and offering expenses. Outlook Therapeutics has the potential to receive additional gross proceeds of up to $99 million upon the full cash exercise of the warrants issued in the private placement, before deducting placement agent fees and offering expenses.
Which stocks are experiencing notable movement on Friday?
Here you can normally see the latest stock twits on OTLK, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: